Showing results (201-210 of 441) with videos related to
Sort By:
Pageof 45
Journal of Neuro-Oncology|September 11, 2015
Primary and secondary gliosarcomas: clinical, molecular and survival characteristicsDavid Cachia, Carlos Kamiya-Matsuoka, Jacob J Mandel, et al.Cancers|July 26, 2020
TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against GlioblastomaEmeline Tabouret, Herui Wang, Niranjana Amin, et al.Neuro-Oncology|October 3, 2002
Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategiesFrederick F Lang, Mark R Gilbert, Vinay K Puduvalli, et al.Neuro-Oncology|March 29, 2018
Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686Jerrold L Boxerman, Zheng Zhang, Yair Safriel, et al.Neuro-Oncology|June 22, 2013
Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader StudyJerrold L Boxerman, Zheng Zhang, Yair Safriel, et al.Journal of Neuro-Oncology|July 25, 2020
Variations in attitudes towards stereotactic biopsy of adult diffuse midline glioma patients: a survey of members of the AANS/CNS Tumor SectionJohn Lynes, Alvina A Acquaye, Hannah Sur, et al.Cancers|October 16, 2025
Correction: Tabouret et al. TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma. <i>Cancers</i> 2020, <i>12</i>, 1935Emeline Tabouret, Herui Wang, Niranjana Amin, et al.Nature Communications|May 31, 2018
Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockadeWinson S Ho, Herui Wang, Dominic Maggio, et al.Journal of Neuro-Oncology|May 17, 2018
Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBMLindsay S Rowe, John A Butman, Megan Mackey, et al.Journal of Neuro-Oncology|April 30, 2014
Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testingBetty Y S Kim, Wen Jiang, Jason Beiko, et al.Pageof 45